Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasted to Post Q1 2022 Earnings of ($0.77) Per Share

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Stock analysts at SVB Leerink issued their Q1 2022 earnings per share estimates for Enanta Pharmaceuticals in a research note issued to investors on Thursday, January 13th. SVB Leerink analyst R. Ruiz expects that the biotechnology company will earn ($0.77) per share for the quarter. SVB Leerink currently has a “Market Perform” rating and a $80.00 target price on the stock. SVB Leerink also issued estimates for Enanta Pharmaceuticals’ Q2 2022 earnings at ($1.07) EPS, Q3 2022 earnings at ($0.96) EPS and Q4 2022 earnings at ($0.82) EPS.

A number of other brokerages have also recently weighed in on ENTA. Royal Bank of Canada reduced their target price on shares of Enanta Pharmaceuticals from $74.00 to $72.00 and set a “sector perform” rating for the company in a report on Friday, November 19th. JMP Securities restated a “buy” rating and set a $116.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, January 5th. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 10th. Jefferies Financial Group began coverage on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 6th. They issued a “buy” rating and a $95.00 price objective for the company. Finally, Roth Capital decreased their price objective on shares of Enanta Pharmaceuticals from $107.00 to $101.00 and set a “buy” rating for the company in a research note on Tuesday, November 23rd. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $89.00.

Shares of NASDAQ:ENTA opened at $60.00 on Friday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -15.35 and a beta of 0.53. Enanta Pharmaceuticals has a 1-year low of $40.37 and a 1-year high of $102.00. The company has a 50 day moving average price of $78.71 and a 200 day moving average price of $63.78.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 22nd. The biotechnology company reported ($1.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.31) by $0.09. The firm had revenue of $23.58 million during the quarter, compared to analysts’ expectations of $35.65 million. Enanta Pharmaceuticals had a negative net margin of 81.38% and a negative return on equity of 18.53%. During the same period last year, the firm posted ($0.55) earnings per share.

Several large investors have recently modified their holdings of ENTA. Royal Bank of Canada raised its holdings in shares of Enanta Pharmaceuticals by 1,367.7% during the 2nd quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 1,313 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Enanta Pharmaceuticals by 103.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,601 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 814 shares in the last quarter. Eaton Vance Management raised its holdings in shares of Enanta Pharmaceuticals by 8.0% during the 3rd quarter. Eaton Vance Management now owns 3,130 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 231 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $217,000. Finally, Metropolitan Life Insurance Co NY raised its holdings in shares of Enanta Pharmaceuticals by 106,140.0% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 5,312 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 5,307 shares in the last quarter. 95.40% of the stock is owned by institutional investors.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 13,523 shares of Enanta Pharmaceuticals stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $86.35, for a total transaction of $1,167,711.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 35,606 shares of company stock valued at $2,857,306 in the last ninety days. Company insiders own 11.74% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Featured Story: Most Volatile Stocks

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.